高剂量流感疫苗在老年人中的有效性与安全性:系统综述与Meta分析
该系统综述与Meta分析纳入7项随机对照试验,比较高剂量(每株60μg血凝素)与标准剂量(每株15μg血凝素)流感疫苗在65岁以上成人中的效果。高剂量组发生实验室确诊流感感染的风险显著降低(相对风险0.76,95%CI 0.65至0.90;I² 0%,2项试验,41,141例患者),免疫原性更高,且两组均无方案定义的严重不良事件。作者认为高剂量疫苗耐受性良好、免疫原性更强且更有效,但需进一步实用性试验确定其更高效力能否转化为更高疫苗有效性。
要点
- 高剂量流感疫苗降低65岁以上成人实验室确诊流感感染风险(相对风险0.76,95%CI 0.65至0.90)。
- 高剂量疫苗接种后几何平均滴度和血清保护率均高于标准剂量组。
- 纳入试验中两组均无方案定义的严重不良事件。
核心结论
- 在老年人中,高剂量流感疫苗耐受性良好、免疫原性更强,且预防流感感染比标准剂量疫苗更有效。
- 需要进一步实用性试验来确定更高的效力能否转化为65岁以上成人更高的疫苗有效性。
研究设计与样本
- 系统综述与Meta分析,检索Medline(Ovid)、EMBASE(Ovid)、Cochrane Library(Wiley)、ClinicalTrials.gov、相关文章参考文献列表和灰色文献中的随机对照试验。
- 由两名评价者独立筛选比较高剂量流感疫苗(每株60μg血凝素)与标准剂量流感疫苗(每株15μg血凝素)在65岁以上成人中效果的随机对照试验。
- 共纳入7项符合条件的试验,所有试验被归类为低偏倚风险(n=3)或不明确偏倚风险(n=4)。
主要发现
- 接受高剂量疫苗的患者发生实验室确诊流感感染的风险显著降低(相对风险0.76,95%CI 0.65至0.90;I² 0%,2项试验,41,141例患者)。
- 高剂量疫苗受种者的接种后几何平均滴度和血清保护率也更高。
- 纳入试验中两组均无方案定义的严重不良事件。
局限性
- 需要进一步实用性试验来确定更高的效力能否转化为65岁以上成人更高的疫苗有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Older adults are prioritized for influenza vaccination but also have lowered antibody responses to the vaccine. Higher-doses of influenza antigen may increase immune response and thus be more effective. Our objectives were to compare the efficacy and safety of the high-dose influenza vaccine to the standard-dose influenza vaccine in the elderly (age>65). METHODS: Data sources: Randomized trials (RCTs) from Medline (Ovid), EMBASE (Ovid), Cochrane Library (Wiley), ClinicalTrials.gov, reference lists of relevant articles, and gray literature. STUDY SELECTION: Two reviewers independently identified RCTs comparing high-dose influenza vaccine (60μg of hemagglutinin per strain) to standard-dose influenza vaccine (15μg of hemagglutinin per strain) in adults over the age of 65years. DATA EXTRACTION: Two reviewers independently extracted trial-level data including population characteristics, interventions, outcomes, and funding sources. Risk of bias was assessed using the Cochrane Risk of Bias tool. RESULTS: We included seven eligible trials; all were categorized as having a low (n=3) or unclear (n=4) risk of bias. Patients receiving the high-dose vaccine had significantly less risk of developing laboratory-confirmed influenza infections (Relative Risk 0.76, 95%CI 0.65 to 0.90; I2 0%, 2 trials, 41,141 patients). Post-vaccination geometric mean titres and seroprotection rates were also higher in high-dose vaccine recipients. There were no protocol-defined serious adverse events in the included trials in either group. CONCLUSIONS: In elderly adults, the high-dose influenza vaccine was well-tolerated, more immunogenic, and more efficacious in preventing influenza infections than the standard-dose vaccine. Further pragmatic trials are needed to determine if the higher efficacy translates into higher vaccine effectiveness in adults over the age of 65.
引用
- Wilkinson K, Wei Y, Szwajcer A, et al. Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis. Vaccine. 2017. PMID: 28431815. doi:10.1016/j.vaccine.2017.03.092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。